Comparison of various requirements of the quality assurance procedures for 18F-FDG injection

Journal of Nuclear Medicine

Volumn 43, Issue 11, 2002, Pages 1495-1506

  Hung, Joseph C ^a  

^a MAYO CLINIC   (United States)

Author keywords

18F FDG injection; Chemistry, Manufacturing, and Controls; European Pharmacopeia; Food and Drug Administration; Quality assurance; U.S. Pharmacopeia

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ARTICLE; DRUG APPROVAL; FOOD AND DRUG ADMINISTRATION; GOOD MANUFACTURING PRACTICE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUALITY CONTROL; STANDARD;

DRUG COMPOUNDING; EUROPE; FLUORODEOXYGLUCOSE F18; INJECTIONS; PHARMACOPOEIAS; QUALITY CONTROL; RADIOPHARMACEUTICALS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 0036843275     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Fludeoxyglucose F 18 injection. In: The United States Pharmacopeia, 25th Ed., and The National Formulary, 20th Ed. Rockville, MD: United States Pharmacopeial Convention, Inc.: 2002:752-753.
2. Positron emission tomography. In: Food and Drug Administration Modernization Act of 1997. Pub L No. 105-115, §121.
3. Fludeoxyglucose F 18 injection CMC section. In: Sample Formats: Application to Manufacture Ammonia N 13 Injection, Fluorodeoxyglucose F 18 Injection (FDG F 18), and Sodium Fluoride F 18 Injection - Chemistry, Manufacturing, and Controls Section. Rockville, MD: Food and Drug Administration; 2000:24-26. Available at: http://www.fda.gov/cder/guidance/cmcsample.pdf. Accessed August 14, 2002.
4. 18F) injection. In: European Pharmacopeia. 4th Ed. Strasbourg, France: European Directorate for the Quality of the Medicines; 2002:2316-2319.
5. Radiopharmaceutical preparation. In: European Pharmacopeia. 4th Ed. Strasbourg, France: European Directorate for the Quality of the Medicines; 2002: 1361-1368.
6. Briner WH. USP monographs and tests of radiopharmaceutical purity [letter]. Am J Health Syst Pharm. 1995;52:1817-1818.
7. Chromatography (general chapter 621). In: The United States Pharmacopeia. 25th Ed., and The National Formulary, 20th Ed. Rockville, MD: United States Pharmacopeial Convention, Inc.; 2002:1982-1995.
8. Facilities and Equipment Guidance: PET Drug Products - Current Good Manufacturing Practice (CGMP). Rockville. MD: Food and Drug Administration; 2002:7-14.
9. 18FDG preparations and detection of the chemical impurity 2-deoxy-2-chloro-D-glucose. Int J Rad Appl Instrum [A]. 1992;43:1313-1322.
10. 18F]fluoro-2-deoxy-D-glucose. Appl Radiat Isot. 1996;47:61-66.
11. 18F]fluoro-2-deoxy-D-glucose towards epimerization under alkaline conditions. Appl Radiat Isot. 1999;51:37-41.
12. 18F]fluoro-2-deoxy-D-glucose using aminopotyether supported nucleophilic substitution. J Nucl Med. 1986;27:235-238.
13. pH. In: The United States Pharmacopeia, 25th ed., and The National Formulary, 20th ed. Rockville, MD: United States Pharmacopeial Convention. Inc.; 2002: 2052-2053.
14. pH/px (test papers & solutions). In: Fisher Catalog 2000/01. Pittsburgh, PA: Fisher Scientific; 2000:1283.
15. 18F]2-fluoro-2-deoxy-D-glucose. Nucl Med Biol. 1989;16: 385-387.
16. 18F]FDG preparation. Nucl Med Biol. 1997;24: 193-195.
17. 18FDG by gas chromatography using a nitrogen-selective detector. Nucl Med Biol. 1993;20:367-369.
18. 4,7,13,16,21,24-Hexaoxa-1,10-diazobicyclo-(8,8,8)hexacosane (Kryptofix 222) [Material Safety Data Sheet]. St. Louis. MO: Sigma-Aldrich; August 3, 2000.
19. Acetonitrile [Material Safety Data Sheet]. Oxford, U.K.: University of Oxford. Available at: http: //www.physchem.ox.ac.uk/MSDS/AC/acetonitrile.html. Accessed August 14. 2002.
20. Anhydrous Alcohol (Reagent Grade) [Material Safety Data Sheet]. Oxford, U.K.: University of Oxford. Available at: http: //www.physchem.ox.ac.uk/MSDS/AL/ alcohol,_anhydrous,_reagent. Accessed August 14, 2002.
21. Diethyl Ether [Material Safety Data Sheet]. Oxford. U.K.: University of Oxford. Available at: http://www.physchem.ox.ac.uk/MSDS/DI/diethyl_ether.html. Accessed August 14, 2002.
22. Classification of residual solvents by risk assessment. In: Guidance for Industry: Q3C Impurities - Residual Solvents. Rockville, MD: Food and Drug Administration; 1997:3. Available at: http: //www.fda.gov/cder/guidance/Q3Cfnl.pdf. Accessed August 14, 2002.
23. Guidance for Industry: Q3C - Tables and List. Rockville, MD: Food and Drug Administration; 1997. Available at: http://www.fda.gov/cder/guid ance/ Q3Ct&l.pdf. Accessed August 14, 2002.
24. Bacterial endotoxins test (general chapter 85). In: The United States Pharmacopeia, 25th Ed., and The National Formulary, 20th Ed. Rockville, MD: United States Pharmacopeial Convention, Inc.; 2002:1889-1893.
25. Finished drug product controls and acceptance criteria. In: Guidance: PET Drug Products - Current Good Manufacturing Practice (CGMP). Rockville, MD: Food and Drug Administration: 2002:27-28.
26. Radiopharmaceuticals for positron emission tomography: Compounding (general chapter 823). In: The United States Pharmacopeia, 25th Ed., and The National Formulary, 20th Ed. Rockville, MD: United States Pharmacopeial Convention, Inc.; 2002:2068-2071.
27. Cooper JF. USP revision for radiopharmaceuticals for positron emission tomography (PET) takes effect June 2001. LAL Times. June 2001;8:1-2.
28. Sterility tests. In: The United States Pharmacopeia, 25th Ed., and The National Formulary, 20th Ed. Rockville, MD: United States Pharmacopeial Convention, Inc.; 2002:1878-1883.
29. Monographs on radiopharmaceutical preparations. In: European Pharmacopeia. 4th Ed. Strasbourg, France: European Directorate for the Quality of the Medicines; 2002:2309-2355.
30. Current Good Manufacturing Practice for Positron Emission Tomography Drugs: Preliminary Draft Proposed Rule. Rockville, MD: Food and Drug Administration; 2002:68.
31. General notices and requirements. In: The United States Pharmacopeia, 25th Ed., and The National Formulary, 20th Ed. Rockville, MD: United States Pharmacopeial Convention, Inc.; 2002:1-11.
32. General notices. In: European Pharmacopeia, 4th Ed. Strasbourg, France: European Directorate for the Quality of the Medicines: 2002;1-12.